S&P 500
5,888.55
-0.6%
-$32.99
DJI
42,098.70
-0.6%
-$244.95
NASDAQ
19,100.94
-0.5%
-$98.23
Bitcoin
108,117.00
-0.7%
-733.53
AAPL
$200.40
+0.1%
+$0.19
AMZN
$204.64
-0.7%
-$1.38
GOOG
$173.28
-0.4%
-$0.70
META
$643.48
+0.2%
+$1.16
MSFT
$457.40
-0.7%
-$3.28
NVDA
$135.14
-0.3%
-$0.36
TSLA
$356.97
-1.6%
-$5.92
Oncolytics Biotech (TSX: ONC)
CA$0.52
(-7.1%)
-CA$0.04
Price as of May 28, 2025, 3:59 p.m. ET
Oncolytics Biotech Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Oncolytics Biotech Company Info
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.